NUVEEN MUN 2021/COM Plans Monthly Dividend of $0.02 (NYSE:NHA)

Share on StockTwits

NUVEEN MUN 2021/COM (NYSE:NHA) declared a monthly dividend on Thursday, August 1st, NASDAQ reports. Investors of record on Thursday, August 15th will be paid a dividend of 0.015 per share on Tuesday, September 3rd. This represents a $0.18 dividend on an annualized basis and a dividend yield of 1.83%. The ex-dividend date is Wednesday, August 14th.

NYSE NHA opened at $9.81 on Tuesday. NUVEEN MUN 2021/COM has a 1 year low of $9.25 and a 1 year high of $9.88. The company has a fifty day moving average of $9.72.

About NUVEEN MUN 2021/COM

Nuveen Municipal 2021 Target Term Fund closed ended fixed income mutual fund launched by Nuveen Investments, Inc The fund is co-managed by Nuveen Fund Advisors, LLC and Nuveen Asset Management, LLC. It invests in fixed income markets of the United States. The fund primarily invests in municipal securities and other related investments, the income from which is exempt from regular federal income tax.

Featured Article: How is the Producer Price Index calculated?

Dividend History for NUVEEN MUN 2021/COM (NYSE:NHA)

Receive News & Ratings for NUVEEN MUN 2021/COM Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NUVEEN MUN 2021/COM and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Zacks Investment Research Downgrades Dunkin Brands Group  to Hold
Zacks Investment Research Downgrades Dunkin Brands Group to Hold
Esperion Therapeutics  Given New $70.00 Price Target at Stifel Nicolaus
Esperion Therapeutics Given New $70.00 Price Target at Stifel Nicolaus
Zacks Investment Research Upgrades First Community  to Hold
Zacks Investment Research Upgrades First Community to Hold
ConnectOne Bancorp  Stock Rating Upgraded by Zacks Investment Research
ConnectOne Bancorp Stock Rating Upgraded by Zacks Investment Research
ValuEngine Lowers Cue Biopharma  to Hold
ValuEngine Lowers Cue Biopharma to Hold
Chimerix  Upgraded by Zacks Investment Research to Hold
Chimerix Upgraded by Zacks Investment Research to Hold


© 2006-2019 Ticker Report